A detailed history of Two Sigma Investments, LP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 66,817 shares of BEAM stock, worth $1.91 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,817
Previous 120,765 44.67%
Holding current value
$1.91 Million
Previous $2.83 Million 42.14%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$22.57 - $33.14 $1.22 Million - $1.79 Million
-53,948 Reduced 44.67%
66,817 $1.64 Million
Q2 2024

Aug 14, 2024

SELL
$21.22 - $32.66 $5.05 Million - $7.77 Million
-238,033 Reduced 66.34%
120,765 $2.83 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $8.42 Million - $16.2 Million
358,798 New
358,798 $11.9 Million
Q2 2023

Aug 14, 2023

SELL
$29.32 - $35.99 $1.58 Million - $1.94 Million
-53,900 Reduced 87.93%
7,400 $236,000
Q1 2023

May 15, 2023

BUY
$30.15 - $48.79 $1.85 Million - $2.99 Million
61,300 New
61,300 $1.88 Million
Q3 2022

Nov 14, 2022

BUY
$39.79 - $70.31 $6.44 Million - $11.4 Million
161,878 Added 436.12%
198,996 $9.48 Million
Q2 2022

Aug 15, 2022

SELL
$29.86 - $62.36 $969,315 - $2.02 Million
-32,462 Reduced 46.65%
37,118 $1.44 Million
Q1 2022

May 16, 2022

BUY
$53.73 - $82.16 $2.43 Million - $3.71 Million
45,214 Added 185.56%
69,580 $3.99 Million
Q4 2021

Feb 14, 2022

SELL
$68.02 - $99.06 $13 Million - $19 Million
-191,331 Reduced 88.7%
24,366 $1.94 Million
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $4.06 Million - $6.43 Million
48,096 Added 28.7%
215,697 $18.8 Million
Q2 2021

Aug 16, 2021

BUY
$64.12 - $128.71 $8.56 Million - $17.2 Million
133,525 Added 391.84%
167,601 $21.6 Million
Q1 2021

May 17, 2021

BUY
$71.28 - $120.75 $2.43 Million - $4.11 Million
34,076 New
34,076 $2.73 Million

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $2.01B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.